Assessment of tocilizumab in the treatment of cancer cachexia

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages 2970-

  Berti, Alvise ^a   Boccalatte, Francesco ^a   Sabbadini, Maria Grazia ^a   Dagna, Lorenzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 6; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; CACHEXIA; HUMAN; IMMUNOCOMPETENT CELL; LARGE CELL CARCINOMA; LETTER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; MUSCLE ATROPHY; MUSCLE MASS; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SARCOPENIA; SIDE EFFECT; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL, HUMANIZED; CACHEXIA; CARCINOMA, LARGE CELL; HUMANS; LUNG NEOPLASMS; MALE; RECEPTORS, INTERLEUKIN-6;

EID: 84889841611     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.4147     Document Type: Letter

References (10)

1. Ando K, Takahashi F, Motojima S, et al: Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol 31:e69-e72, 2013
2. Nishimoto N, Terao K, Mima T, et al: Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112:3959-3964, 2008
3. Laviano A, Meguid MM, Inui A, et al: Therapy insight: Cancer anorexia-cachexia syndrome - When all you can eat is yourself. Nat Clin Pract Oncol 2:158-165, 2005
4. Chang CH, Hsiao CF, Yeh YM, et al: Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 132:1977-1985, 2013
5. European Medicines Agency: RoActemra, EPAR: Product Information. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000955/WC500054890.pdf
6. Monk JP, Phillips G, Waite R, et al: Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 24:1852-1859, 2006
7. Schultz DR, Arnold PI: Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum 20:129-147, 1990
8. Tan BH, Birdsell LA, Martin L, et al: Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 15:6973-6979, 2009
9. Carson JA, Baltgalvis KA: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev 38:168-176, 2010
10. Chumlea WC, Guo SS, Vellas B, et al: Techniques of assessing muscle mass and function (sarcopenia) for epidemiological studies of the elderly. J Gerontol A Biol Sci Med Sci 50 Spec No:45-51, 1995